1. What is the projected Compound Annual Growth Rate (CAGR) of the Artificial Intelligence in Drug Discovery and Development?
The projected CAGR is approximately XX%.
Artificial Intelligence in Drug Discovery and DevelopmentArtificial Intelligence in Drug Discovery and Development XX CAGR Growth Outlook 2025-2033
Artificial Intelligence in Drug Discovery and Development by Type (Hardware, Software, Service), by Application (Early Drug Discovery, Preclinical Phase, Clinical Phase, Regulatory Approval), by North America (United States, Canada, Mexico), by South America (Brazil, Argentina, Rest of South America), by Europe (United Kingdom, Germany, France, Italy, Spain, Russia, Benelux, Nordics, Rest of Europe), by Middle East & Africa (Turkey, Israel, GCC, North Africa, South Africa, Rest of Middle East & Africa), by Asia Pacific (China, India, Japan, South Korea, ASEAN, Oceania, Rest of Asia Pacific) Forecast 2025-2033
Base Year: 2024
174 Pages
Artificial Intelligence in Drug Discovery and Development XX CAGR Growth Outlook 2025-2033
Artificial Intelligence in Drug Discovery and Development XX CAGR Growth Outlook 2025-2033
Key Insights
Market Analysis: Artificial Intelligence in Drug Discovery and Development
The global market for Artificial Intelligence (AI) in drug discovery and development is anticipated to witness robust growth, reaching a projected value of 8511.6 million by 2033, expanding at a CAGR of XX% during the forecast period from 2025 to 2033. Key drivers fueling this growth include the rising prevalence of chronic diseases, increased R&D spending by pharmaceutical and biotech companies, and government initiatives to accelerate drug innovation. Advancements in AI technologies, such as machine learning, deep learning, and natural language processing, are revolutionizing various stages of the drug development process, from early target identification to preclinical and clinical trials to regulatory approvals.
The AI-powered drug discovery and development market is characterized by the presence of both established companies and emerging startups. Major players include IBM, Exscientia, Google (Alphabet), Microsoft, Atomwise, and Schrodinger. The market is segmented based on type (hardware, software, service) and application (early drug discovery, preclinical phase, clinical phase, regulatory approval). North America and Europe are expected to remain dominant regions throughout the forecast period, driven by high levels of healthcare expenditure and technological advancement. Asia Pacific is also projected to witness significant growth due to a rapidly expanding healthcare market and government support for AI adoption.
Artificial Intelligence in Drug Discovery and Development Trends
The global AI in drug discovery and development market is projected to reach $22.1 billion by 2032, growing at a CAGR of 45.4% from 2023 to 2032. This growth is attributed to the increasing adoption of AI technologies in the pharmaceutical and biotechnology industries, as well as the growing need for new and innovative drug therapies. The increasing prevalence of chronic diseases, the rising cost of drug development, and the need to improve the efficiency of drug discovery and development processes are also driving the growth of this market.
Driving Forces: What's Propelling the Artificial Intelligence in Drug Discovery and Development
The increasing adoption of AI technologies in the pharmaceutical and biotechnology industries is a major driving force behind the growth of the AI in drug discovery and development market. AI technologies can be used to automate tasks, such as data analysis and screening, which can free up researchers to focus on more creative and strategic work. AI can also be used to develop new drug therapies, such as personalized medicine, which can be tailored to the individual needs of patients.
Challenges and Restraints in Artificial Intelligence in Drug Discovery and Development
The high cost of AI technologies is a major challenge facing the AI in drug discovery and development market. The lack of skilled professionals who are trained in AI technologies is also a challenge. Additionally, the regulatory environment for AI technologies is still evolving, which can create uncertainty for companies that are considering investing in AI technologies.
Key Region or Country & Segment to Dominate the Market
North America is expected to dominate the AI in drug discovery and development market throughout the forecast period. The United States is the largest market for AI in drug discovery and development in North America, and it is expected to continue to lead the market over the next decade. The high adoption of AI technologies in the pharmaceutical and biotechnology industries in the United States is driving the growth of the market in this region.
The software segment is expected to dominate the AI in drug discovery and development market throughout the forecast period. The software segment includes AI platforms and algorithms that can be used to automate tasks, such as data analysis and screening. The growing demand for AI software to improve the efficiency of drug discovery and development processes is driving the growth of this segment.
Growth Catalysts in Artificial Intelligence in Drug Discovery and Development Industry
The increasing prevalence of chronic diseases is a major growth catalyst for the AI in drug discovery and development market. The rising cost of drug development is also a growth catalyst for the market. The need to improve the efficiency of drug discovery and development processes is also driving the growth of the market.
Leading Players in the Artificial Intelligence in Drug Discovery and Development
Some of the leading players in the AI in drug discovery and development market include:
- IBM
- Exscientia
- Microsoft
- Atomwise
- Schrodinger
- Aitia
- Insilico Medicine
- NVIDIA
- XtalPi
- BPGbio
- Owkin
- CytoReason
- Deep Genomics
- Cloud Pharmaceuticals
- BenevolentAI
- Cyclica
- Verge Genomics
- Valo Health
- Envisagenics
- Euretos
- BioAge Labs
- Iktos
- BioSymetrics
- Evaxion Biotech
- Aria Pharmaceuticals, Inc
Significant Developments in Artificial Intelligence in Drug Discovery and Development Sector
Some of the significant developments in the AI in drug discovery and development sector include:
- In 2020, IBM launched Watson for Drug Discovery, a cloud-based platform that uses AI to accelerate drug discovery and development.
- In 2021, Exscientia announced a partnership with Roche to develop AI-powered drug therapies for oncology.
- In 2022, Google and DeepMind announced a partnership to develop AI systems for drug discovery.
Comprehensive Coverage Artificial Intelligence in Drug Discovery and Development Report
This report provides comprehensive coverage of the AI in drug discovery and development market, including an overview of the market, market dynamics, and market trends. The report also provides detailed analysis of the competitive landscape, as well as forecasts for market growth.
Artificial Intelligence in Drug Discovery and Development Segmentation
-
1. Type
- 1.1. Hardware
- 1.2. Software
- 1.3. Service
-
2. Application
- 2.1. Early Drug Discovery
- 2.2. Preclinical Phase
- 2.3. Clinical Phase
- 2.4. Regulatory Approval
Artificial Intelligence in Drug Discovery and Development Segmentation By Geography
-
1. North America
- 1.1. United States
- 1.2. Canada
- 1.3. Mexico
-
2. South America
- 2.1. Brazil
- 2.2. Argentina
- 2.3. Rest of South America
-
3. Europe
- 3.1. United Kingdom
- 3.2. Germany
- 3.3. France
- 3.4. Italy
- 3.5. Spain
- 3.6. Russia
- 3.7. Benelux
- 3.8. Nordics
- 3.9. Rest of Europe
-
4. Middle East & Africa
- 4.1. Turkey
- 4.2. Israel
- 4.3. GCC
- 4.4. North Africa
- 4.5. South Africa
- 4.6. Rest of Middle East & Africa
-
5. Asia Pacific
- 5.1. China
- 5.2. India
- 5.3. Japan
- 5.4. South Korea
- 5.5. ASEAN
- 5.6. Oceania
- 5.7. Rest of Asia Pacific
Artificial Intelligence in Drug Discovery and Development REPORT HIGHLIGHTS
| Aspects | Details |
|---|---|
| Study Period | 2019-2033 |
| Base Year | 2024 |
| Estimated Year | 2025 |
| Forecast Period | 2025-2033 |
| Historical Period | 2019-2024 |
| Growth Rate | CAGR of XX% from 2019-2033 |
| Segmentation |
|
Table of Contents
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 2.1. Introduction
- 3. Market Dynamics
- 3.1. Introduction
- 3.2. Market Drivers
- 3.3. Market Restrains
- 3.4. Market Trends
- 4. Market Factor Analysis
- 4.1. Porters Five Forces
- 4.2. Supply/Value Chain
- 4.3. PESTEL analysis
- 4.4. Market Entropy
- 4.5. Patent/Trademark Analysis
- 5. Global Artificial Intelligence in Drug Discovery and Development Analysis, Insights and Forecast, 2019-2031
- 5.1. Market Analysis, Insights and Forecast - by Type
- 5.1.1. Hardware
- 5.1.2. Software
- 5.1.3. Service
- 5.2. Market Analysis, Insights and Forecast - by Application
- 5.2.1. Early Drug Discovery
- 5.2.2. Preclinical Phase
- 5.2.3. Clinical Phase
- 5.2.4. Regulatory Approval
- 5.3. Market Analysis, Insights and Forecast - by Region
- 5.3.1. North America
- 5.3.2. South America
- 5.3.3. Europe
- 5.3.4. Middle East & Africa
- 5.3.5. Asia Pacific
- 5.1. Market Analysis, Insights and Forecast - by Type
- 6. North America Artificial Intelligence in Drug Discovery and Development Analysis, Insights and Forecast, 2019-2031
- 6.1. Market Analysis, Insights and Forecast - by Type
- 6.1.1. Hardware
- 6.1.2. Software
- 6.1.3. Service
- 6.2. Market Analysis, Insights and Forecast - by Application
- 6.2.1. Early Drug Discovery
- 6.2.2. Preclinical Phase
- 6.2.3. Clinical Phase
- 6.2.4. Regulatory Approval
- 6.1. Market Analysis, Insights and Forecast - by Type
- 7. South America Artificial Intelligence in Drug Discovery and Development Analysis, Insights and Forecast, 2019-2031
- 7.1. Market Analysis, Insights and Forecast - by Type
- 7.1.1. Hardware
- 7.1.2. Software
- 7.1.3. Service
- 7.2. Market Analysis, Insights and Forecast - by Application
- 7.2.1. Early Drug Discovery
- 7.2.2. Preclinical Phase
- 7.2.3. Clinical Phase
- 7.2.4. Regulatory Approval
- 7.1. Market Analysis, Insights and Forecast - by Type
- 8. Europe Artificial Intelligence in Drug Discovery and Development Analysis, Insights and Forecast, 2019-2031
- 8.1. Market Analysis, Insights and Forecast - by Type
- 8.1.1. Hardware
- 8.1.2. Software
- 8.1.3. Service
- 8.2. Market Analysis, Insights and Forecast - by Application
- 8.2.1. Early Drug Discovery
- 8.2.2. Preclinical Phase
- 8.2.3. Clinical Phase
- 8.2.4. Regulatory Approval
- 8.1. Market Analysis, Insights and Forecast - by Type
- 9. Middle East & Africa Artificial Intelligence in Drug Discovery and Development Analysis, Insights and Forecast, 2019-2031
- 9.1. Market Analysis, Insights and Forecast - by Type
- 9.1.1. Hardware
- 9.1.2. Software
- 9.1.3. Service
- 9.2. Market Analysis, Insights and Forecast - by Application
- 9.2.1. Early Drug Discovery
- 9.2.2. Preclinical Phase
- 9.2.3. Clinical Phase
- 9.2.4. Regulatory Approval
- 9.1. Market Analysis, Insights and Forecast - by Type
- 10. Asia Pacific Artificial Intelligence in Drug Discovery and Development Analysis, Insights and Forecast, 2019-2031
- 10.1. Market Analysis, Insights and Forecast - by Type
- 10.1.1. Hardware
- 10.1.2. Software
- 10.1.3. Service
- 10.2. Market Analysis, Insights and Forecast - by Application
- 10.2.1. Early Drug Discovery
- 10.2.2. Preclinical Phase
- 10.2.3. Clinical Phase
- 10.2.4. Regulatory Approval
- 10.1. Market Analysis, Insights and Forecast - by Type
- 11. Competitive Analysis
- 11.1. Global Market Share Analysis 2024
- 11.2. Company Profiles
- 11.2.1 IBM
- 11.2.1.1. Overview
- 11.2.1.2. Products
- 11.2.1.3. SWOT Analysis
- 11.2.1.4. Recent Developments
- 11.2.1.5. Financials (Based on Availability)
- 11.2.2 Exscientia
- 11.2.2.1. Overview
- 11.2.2.2. Products
- 11.2.2.3. SWOT Analysis
- 11.2.2.4. Recent Developments
- 11.2.2.5. Financials (Based on Availability)
- 11.2.3 Google(Alphabet)
- 11.2.3.1. Overview
- 11.2.3.2. Products
- 11.2.3.3. SWOT Analysis
- 11.2.3.4. Recent Developments
- 11.2.3.5. Financials (Based on Availability)
- 11.2.4 Microsoft
- 11.2.4.1. Overview
- 11.2.4.2. Products
- 11.2.4.3. SWOT Analysis
- 11.2.4.4. Recent Developments
- 11.2.4.5. Financials (Based on Availability)
- 11.2.5 Atomwise
- 11.2.5.1. Overview
- 11.2.5.2. Products
- 11.2.5.3. SWOT Analysis
- 11.2.5.4. Recent Developments
- 11.2.5.5. Financials (Based on Availability)
- 11.2.6 Schrodinger
- 11.2.6.1. Overview
- 11.2.6.2. Products
- 11.2.6.3. SWOT Analysis
- 11.2.6.4. Recent Developments
- 11.2.6.5. Financials (Based on Availability)
- 11.2.7 Aitia
- 11.2.7.1. Overview
- 11.2.7.2. Products
- 11.2.7.3. SWOT Analysis
- 11.2.7.4. Recent Developments
- 11.2.7.5. Financials (Based on Availability)
- 11.2.8 Insilico Medicine
- 11.2.8.1. Overview
- 11.2.8.2. Products
- 11.2.8.3. SWOT Analysis
- 11.2.8.4. Recent Developments
- 11.2.8.5. Financials (Based on Availability)
- 11.2.9 NVIDIA
- 11.2.9.1. Overview
- 11.2.9.2. Products
- 11.2.9.3. SWOT Analysis
- 11.2.9.4. Recent Developments
- 11.2.9.5. Financials (Based on Availability)
- 11.2.10 XtalPi
- 11.2.10.1. Overview
- 11.2.10.2. Products
- 11.2.10.3. SWOT Analysis
- 11.2.10.4. Recent Developments
- 11.2.10.5. Financials (Based on Availability)
- 11.2.11 BPGbio
- 11.2.11.1. Overview
- 11.2.11.2. Products
- 11.2.11.3. SWOT Analysis
- 11.2.11.4. Recent Developments
- 11.2.11.5. Financials (Based on Availability)
- 11.2.12 Owkin
- 11.2.12.1. Overview
- 11.2.12.2. Products
- 11.2.12.3. SWOT Analysis
- 11.2.12.4. Recent Developments
- 11.2.12.5. Financials (Based on Availability)
- 11.2.13 CytoReason
- 11.2.13.1. Overview
- 11.2.13.2. Products
- 11.2.13.3. SWOT Analysis
- 11.2.13.4. Recent Developments
- 11.2.13.5. Financials (Based on Availability)
- 11.2.14 Deep Genomics
- 11.2.14.1. Overview
- 11.2.14.2. Products
- 11.2.14.3. SWOT Analysis
- 11.2.14.4. Recent Developments
- 11.2.14.5. Financials (Based on Availability)
- 11.2.15 Cloud Pharmaceuticals
- 11.2.15.1. Overview
- 11.2.15.2. Products
- 11.2.15.3. SWOT Analysis
- 11.2.15.4. Recent Developments
- 11.2.15.5. Financials (Based on Availability)
- 11.2.16 BenevolentAI
- 11.2.16.1. Overview
- 11.2.16.2. Products
- 11.2.16.3. SWOT Analysis
- 11.2.16.4. Recent Developments
- 11.2.16.5. Financials (Based on Availability)
- 11.2.17 Cyclica
- 11.2.17.1. Overview
- 11.2.17.2. Products
- 11.2.17.3. SWOT Analysis
- 11.2.17.4. Recent Developments
- 11.2.17.5. Financials (Based on Availability)
- 11.2.18 Verge Genomics
- 11.2.18.1. Overview
- 11.2.18.2. Products
- 11.2.18.3. SWOT Analysis
- 11.2.18.4. Recent Developments
- 11.2.18.5. Financials (Based on Availability)
- 11.2.19 Valo Health
- 11.2.19.1. Overview
- 11.2.19.2. Products
- 11.2.19.3. SWOT Analysis
- 11.2.19.4. Recent Developments
- 11.2.19.5. Financials (Based on Availability)
- 11.2.20 Envisagenics
- 11.2.20.1. Overview
- 11.2.20.2. Products
- 11.2.20.3. SWOT Analysis
- 11.2.20.4. Recent Developments
- 11.2.20.5. Financials (Based on Availability)
- 11.2.21 Euretos
- 11.2.21.1. Overview
- 11.2.21.2. Products
- 11.2.21.3. SWOT Analysis
- 11.2.21.4. Recent Developments
- 11.2.21.5. Financials (Based on Availability)
- 11.2.22 BioAge Labs
- 11.2.22.1. Overview
- 11.2.22.2. Products
- 11.2.22.3. SWOT Analysis
- 11.2.22.4. Recent Developments
- 11.2.22.5. Financials (Based on Availability)
- 11.2.23 Iktos
- 11.2.23.1. Overview
- 11.2.23.2. Products
- 11.2.23.3. SWOT Analysis
- 11.2.23.4. Recent Developments
- 11.2.23.5. Financials (Based on Availability)
- 11.2.24 BioSymetrics
- 11.2.24.1. Overview
- 11.2.24.2. Products
- 11.2.24.3. SWOT Analysis
- 11.2.24.4. Recent Developments
- 11.2.24.5. Financials (Based on Availability)
- 11.2.25 Evaxion Biotech
- 11.2.25.1. Overview
- 11.2.25.2. Products
- 11.2.25.3. SWOT Analysis
- 11.2.25.4. Recent Developments
- 11.2.25.5. Financials (Based on Availability)
- 11.2.26 Aria Pharmaceuticals Inc
- 11.2.26.1. Overview
- 11.2.26.2. Products
- 11.2.26.3. SWOT Analysis
- 11.2.26.4. Recent Developments
- 11.2.26.5. Financials (Based on Availability)
- 11.2.27
- 11.2.27.1. Overview
- 11.2.27.2. Products
- 11.2.27.3. SWOT Analysis
- 11.2.27.4. Recent Developments
- 11.2.27.5. Financials (Based on Availability)
- 11.2.1 IBM
List of Figures
- Figure 1: Global Artificial Intelligence in Drug Discovery and Development Revenue Breakdown (million, %) by Region 2024 & 2032
- Figure 2: North America Artificial Intelligence in Drug Discovery and Development Revenue (million), by Type 2024 & 2032
- Figure 3: North America Artificial Intelligence in Drug Discovery and Development Revenue Share (%), by Type 2024 & 2032
- Figure 4: North America Artificial Intelligence in Drug Discovery and Development Revenue (million), by Application 2024 & 2032
- Figure 5: North America Artificial Intelligence in Drug Discovery and Development Revenue Share (%), by Application 2024 & 2032
- Figure 6: North America Artificial Intelligence in Drug Discovery and Development Revenue (million), by Country 2024 & 2032
- Figure 7: North America Artificial Intelligence in Drug Discovery and Development Revenue Share (%), by Country 2024 & 2032
- Figure 8: South America Artificial Intelligence in Drug Discovery and Development Revenue (million), by Type 2024 & 2032
- Figure 9: South America Artificial Intelligence in Drug Discovery and Development Revenue Share (%), by Type 2024 & 2032
- Figure 10: South America Artificial Intelligence in Drug Discovery and Development Revenue (million), by Application 2024 & 2032
- Figure 11: South America Artificial Intelligence in Drug Discovery and Development Revenue Share (%), by Application 2024 & 2032
- Figure 12: South America Artificial Intelligence in Drug Discovery and Development Revenue (million), by Country 2024 & 2032
- Figure 13: South America Artificial Intelligence in Drug Discovery and Development Revenue Share (%), by Country 2024 & 2032
- Figure 14: Europe Artificial Intelligence in Drug Discovery and Development Revenue (million), by Type 2024 & 2032
- Figure 15: Europe Artificial Intelligence in Drug Discovery and Development Revenue Share (%), by Type 2024 & 2032
- Figure 16: Europe Artificial Intelligence in Drug Discovery and Development Revenue (million), by Application 2024 & 2032
- Figure 17: Europe Artificial Intelligence in Drug Discovery and Development Revenue Share (%), by Application 2024 & 2032
- Figure 18: Europe Artificial Intelligence in Drug Discovery and Development Revenue (million), by Country 2024 & 2032
- Figure 19: Europe Artificial Intelligence in Drug Discovery and Development Revenue Share (%), by Country 2024 & 2032
- Figure 20: Middle East & Africa Artificial Intelligence in Drug Discovery and Development Revenue (million), by Type 2024 & 2032
- Figure 21: Middle East & Africa Artificial Intelligence in Drug Discovery and Development Revenue Share (%), by Type 2024 & 2032
- Figure 22: Middle East & Africa Artificial Intelligence in Drug Discovery and Development Revenue (million), by Application 2024 & 2032
- Figure 23: Middle East & Africa Artificial Intelligence in Drug Discovery and Development Revenue Share (%), by Application 2024 & 2032
- Figure 24: Middle East & Africa Artificial Intelligence in Drug Discovery and Development Revenue (million), by Country 2024 & 2032
- Figure 25: Middle East & Africa Artificial Intelligence in Drug Discovery and Development Revenue Share (%), by Country 2024 & 2032
- Figure 26: Asia Pacific Artificial Intelligence in Drug Discovery and Development Revenue (million), by Type 2024 & 2032
- Figure 27: Asia Pacific Artificial Intelligence in Drug Discovery and Development Revenue Share (%), by Type 2024 & 2032
- Figure 28: Asia Pacific Artificial Intelligence in Drug Discovery and Development Revenue (million), by Application 2024 & 2032
- Figure 29: Asia Pacific Artificial Intelligence in Drug Discovery and Development Revenue Share (%), by Application 2024 & 2032
- Figure 30: Asia Pacific Artificial Intelligence in Drug Discovery and Development Revenue (million), by Country 2024 & 2032
- Figure 31: Asia Pacific Artificial Intelligence in Drug Discovery and Development Revenue Share (%), by Country 2024 & 2032
List of Tables
- Table 1: Global Artificial Intelligence in Drug Discovery and Development Revenue million Forecast, by Region 2019 & 2032
- Table 2: Global Artificial Intelligence in Drug Discovery and Development Revenue million Forecast, by Type 2019 & 2032
- Table 3: Global Artificial Intelligence in Drug Discovery and Development Revenue million Forecast, by Application 2019 & 2032
- Table 4: Global Artificial Intelligence in Drug Discovery and Development Revenue million Forecast, by Region 2019 & 2032
- Table 5: Global Artificial Intelligence in Drug Discovery and Development Revenue million Forecast, by Type 2019 & 2032
- Table 6: Global Artificial Intelligence in Drug Discovery and Development Revenue million Forecast, by Application 2019 & 2032
- Table 7: Global Artificial Intelligence in Drug Discovery and Development Revenue million Forecast, by Country 2019 & 2032
- Table 8: United States Artificial Intelligence in Drug Discovery and Development Revenue (million) Forecast, by Application 2019 & 2032
- Table 9: Canada Artificial Intelligence in Drug Discovery and Development Revenue (million) Forecast, by Application 2019 & 2032
- Table 10: Mexico Artificial Intelligence in Drug Discovery and Development Revenue (million) Forecast, by Application 2019 & 2032
- Table 11: Global Artificial Intelligence in Drug Discovery and Development Revenue million Forecast, by Type 2019 & 2032
- Table 12: Global Artificial Intelligence in Drug Discovery and Development Revenue million Forecast, by Application 2019 & 2032
- Table 13: Global Artificial Intelligence in Drug Discovery and Development Revenue million Forecast, by Country 2019 & 2032
- Table 14: Brazil Artificial Intelligence in Drug Discovery and Development Revenue (million) Forecast, by Application 2019 & 2032
- Table 15: Argentina Artificial Intelligence in Drug Discovery and Development Revenue (million) Forecast, by Application 2019 & 2032
- Table 16: Rest of South America Artificial Intelligence in Drug Discovery and Development Revenue (million) Forecast, by Application 2019 & 2032
- Table 17: Global Artificial Intelligence in Drug Discovery and Development Revenue million Forecast, by Type 2019 & 2032
- Table 18: Global Artificial Intelligence in Drug Discovery and Development Revenue million Forecast, by Application 2019 & 2032
- Table 19: Global Artificial Intelligence in Drug Discovery and Development Revenue million Forecast, by Country 2019 & 2032
- Table 20: United Kingdom Artificial Intelligence in Drug Discovery and Development Revenue (million) Forecast, by Application 2019 & 2032
- Table 21: Germany Artificial Intelligence in Drug Discovery and Development Revenue (million) Forecast, by Application 2019 & 2032
- Table 22: France Artificial Intelligence in Drug Discovery and Development Revenue (million) Forecast, by Application 2019 & 2032
- Table 23: Italy Artificial Intelligence in Drug Discovery and Development Revenue (million) Forecast, by Application 2019 & 2032
- Table 24: Spain Artificial Intelligence in Drug Discovery and Development Revenue (million) Forecast, by Application 2019 & 2032
- Table 25: Russia Artificial Intelligence in Drug Discovery and Development Revenue (million) Forecast, by Application 2019 & 2032
- Table 26: Benelux Artificial Intelligence in Drug Discovery and Development Revenue (million) Forecast, by Application 2019 & 2032
- Table 27: Nordics Artificial Intelligence in Drug Discovery and Development Revenue (million) Forecast, by Application 2019 & 2032
- Table 28: Rest of Europe Artificial Intelligence in Drug Discovery and Development Revenue (million) Forecast, by Application 2019 & 2032
- Table 29: Global Artificial Intelligence in Drug Discovery and Development Revenue million Forecast, by Type 2019 & 2032
- Table 30: Global Artificial Intelligence in Drug Discovery and Development Revenue million Forecast, by Application 2019 & 2032
- Table 31: Global Artificial Intelligence in Drug Discovery and Development Revenue million Forecast, by Country 2019 & 2032
- Table 32: Turkey Artificial Intelligence in Drug Discovery and Development Revenue (million) Forecast, by Application 2019 & 2032
- Table 33: Israel Artificial Intelligence in Drug Discovery and Development Revenue (million) Forecast, by Application 2019 & 2032
- Table 34: GCC Artificial Intelligence in Drug Discovery and Development Revenue (million) Forecast, by Application 2019 & 2032
- Table 35: North Africa Artificial Intelligence in Drug Discovery and Development Revenue (million) Forecast, by Application 2019 & 2032
- Table 36: South Africa Artificial Intelligence in Drug Discovery and Development Revenue (million) Forecast, by Application 2019 & 2032
- Table 37: Rest of Middle East & Africa Artificial Intelligence in Drug Discovery and Development Revenue (million) Forecast, by Application 2019 & 2032
- Table 38: Global Artificial Intelligence in Drug Discovery and Development Revenue million Forecast, by Type 2019 & 2032
- Table 39: Global Artificial Intelligence in Drug Discovery and Development Revenue million Forecast, by Application 2019 & 2032
- Table 40: Global Artificial Intelligence in Drug Discovery and Development Revenue million Forecast, by Country 2019 & 2032
- Table 41: China Artificial Intelligence in Drug Discovery and Development Revenue (million) Forecast, by Application 2019 & 2032
- Table 42: India Artificial Intelligence in Drug Discovery and Development Revenue (million) Forecast, by Application 2019 & 2032
- Table 43: Japan Artificial Intelligence in Drug Discovery and Development Revenue (million) Forecast, by Application 2019 & 2032
- Table 44: South Korea Artificial Intelligence in Drug Discovery and Development Revenue (million) Forecast, by Application 2019 & 2032
- Table 45: ASEAN Artificial Intelligence in Drug Discovery and Development Revenue (million) Forecast, by Application 2019 & 2032
- Table 46: Oceania Artificial Intelligence in Drug Discovery and Development Revenue (million) Forecast, by Application 2019 & 2032
- Table 47: Rest of Asia Pacific Artificial Intelligence in Drug Discovery and Development Revenue (million) Forecast, by Application 2019 & 2032
Methodology
Step 1 - Identification of Relevant Samples Size from Population Database
Step 2 - Approaches for Defining Global Market Size (Value, Volume* & Price*)
Top-down and bottom-up approaches are used to validate the global market size and estimate the market size for manufactures, regional segments, product, and application.
Note*: In applicable scenarios
Step 3 - Data Sources
Primary Research
- Web Analytics
- Survey Reports
- Research Institute
- Latest Research Reports
- Opinion Leaders
Secondary Research
- Annual Reports
- White Paper
- Latest Press Release
- Industry Association
- Paid Database
- Investor Presentations
Step 4 - Data Triangulation
Involves using different sources of information in order to increase the validity of a study
These sources are likely to be stakeholders in a program - participants, other researchers, program staff, other community members, and so on.
Then we put all data in single framework & apply various statistical tools to find out the dynamic on the market.
During the analysis stage, feedback from the stakeholder groups would be compared to determine areas of agreement as well as areas of divergence
Additionally, after gathering mixed and scattered data from a wide range of sources, data is triangulated and correlated to come up with estimated figures which are further validated through primary mediums or industry experts, opinion leaders.
Frequently Asked Questions
2. Which companies are prominent players in the Artificial Intelligence in Drug Discovery and Development?
Key companies in the market include IBM, Exscientia, Google(Alphabet), Microsoft, Atomwise, Schrodinger, Aitia, Insilico Medicine, NVIDIA, XtalPi, BPGbio, Owkin, CytoReason, Deep Genomics, Cloud Pharmaceuticals, BenevolentAI, Cyclica, Verge Genomics, Valo Health, Envisagenics, Euretos, BioAge Labs, Iktos, BioSymetrics, Evaxion Biotech, Aria Pharmaceuticals, Inc, .
3. What are the main segments of the Artificial Intelligence in Drug Discovery and Development?
The market segments include Type, Application.
4. Can you provide details about the market size?
The market size is estimated to be USD 8511.6 million as of 2022.
5. What are some drivers contributing to market growth?
N/A
6. What are the notable trends driving market growth?
N/A
7. Are there any restraints impacting market growth?
N/A
8. Can you provide examples of recent developments in the market?
N/A
9. What pricing options are available for accessing the report?
Pricing options include single-user, multi-user, and enterprise licenses priced at USD 4480.00, USD 6720.00, and USD 8960.00 respectively.
10. Is the market size provided in terms of value or volume?
The market size is provided in terms of value, measured in million.
11. Are there any specific market keywords associated with the report?
Yes, the market keyword associated with the report is "Artificial Intelligence in Drug Discovery and Development," which aids in identifying and referencing the specific market segment covered.
12. How do I determine which pricing option suits my needs best?
The pricing options vary based on user requirements and access needs. Individual users may opt for single-user licenses, while businesses requiring broader access may choose multi-user or enterprise licenses for cost-effective access to the report.
13. Are there any additional resources or data provided in the Artificial Intelligence in Drug Discovery and Development report?
While the report offers comprehensive insights, it's advisable to review the specific contents or supplementary materials provided to ascertain if additional resources or data are available.
14. How can I stay updated on further developments or reports in the Artificial Intelligence in Drug Discovery and Development?
To stay informed about further developments, trends, and reports in the Artificial Intelligence in Drug Discovery and Development, consider subscribing to industry newsletters, following relevant companies and organizations, or regularly checking reputable industry news sources and publications.